The purpose of this analysis was to assess the effect of novel agent-based regimens on the
improvement of renal impairment (RI) in newly diagnosed patients with multiple myeloma.
Ninety-six consecutive patients with RI received conventional chemotherapy (CC)-based
regimens (n= 32), IMiDs-based regimens (n= 47) or bortezomib-based regimens (n= 17) as
frontline therapy. Improvement of RI was more frequent in patients treated with novel agents
(79% in IMiD-and 94% in bortezomib-treated groups versus 59% in CC-treated group; p …